FDAnews
www.fdanews.com/articles/159699-vivaldi-buys-flu-vaccine-rd-assets-from-baxter

Vivaldi Buys Flu Vaccine R&D Assets from Baxter

October 14, 2013
Vivaldi Biosciencies has acquired R&D assets for live attenuated influenza vaccines; this includes intellectual property, clinical data and materials.
Genetic Engineering & Biotechnology News